Objective: Fructose bisphosphate aldolase (ALDOB) is a glycolytic metabolic enzyme, which is considered to be a therapeutic target for many cancers. However, ALDOB expression level and its regulatory mechanism in renal clear cell carcinoma is not clear. To explore ALDOB expression level and its regulatory mechanism in renal clear cell carcinoma we downloaded gene expression data sets and analyzed them by bioinformatics. Methods: The gene expression data sets of GSE53757, GSE40435 and GSE105261 about human renal clear cell carcinoma were downloaded from the GEO database and analyzed by using the Venn diagram. We analyzed and screened out the relationship network of the interested target genes through GeneMANIA and STRING online software. These 6 target genes obtained were analyzed by Kaplan-Meier curve. GO enrichment analysis of the target gene ALDOB was performed by DAVID, and the relationship between the expression of ALDOB and immune infiltration in clear cell renal cell carcinoma was analyzed by means of TIMER and TISIDB databases. Finally, a prognostic nomogram was constructed to predict the individual’s 3-year and 5-year survival probabilities. Results: ALDOB gene is positively correlated to the survival and prognosis of patients with renal clear cell carcinoma. Furthermore, the overexpression of ALDOB can prolong the survival time of ccRCC patients. In addition, ALDOB can affect the ratio of CD4+T/CD8+T cells to influence renal clear cell carcinoma. Finally, the main mechanism of its overexpression prolonging the survival time of renal clear cell carcinoma may be involved in glycolysis. Conclusions: These data showed that ALDOB gene could be a biomarker and therapeutic target for renal clear cell carcinoma